| Disease | FIFTY MEN WITH PREVIOUSLY UNTREATED LUTS AND A MINIMUM INTERNATIONAL PROSTATE SYMPTOM SCORE(IPSS) OF 10 OR GREATER WERE TREATED WITH COMMERCIALLY AVAILABLE FORM OF SAW PALMETTO (160 MG TWICE PER DAY) FOR 6 MONTHS. THE INITIAL EVALUATION
MEASUREMENT OF PEAK URINARY FLOW RATE, POSTVOID RESIDUAL URINE VOLUME, PRESSURE-FLOW STUDY, AND SERUM PROSTATE-SPECIFIC ANTIGEN (PSA) LEVEL. PATIENTS COMPLETED AN IPSS, SERUM PSA WAS DETERMINED, AND FLOW RATE WAS MEASURED EVERY 2 MONTHS DURING
THE COURSE OF THE STUDY. A URODYNAMIC EVALUATION WAS REPEATED AT THE COMPLETION OF THE 6-MONTH TRIAL. THE MEAN IPSS(+/-SD) IMPROVED FROM 19.5 +/- 5.5 TO 12.5 +/- 7.0(P<0.001) AMONG THE 46 MEN WHO COMPLETED THE STUDY. SIGNIFICANT IMPROVEMENT IN
THE SYMPTOM SCORE WAS NOTED AFTER TREATMENT WITH SAW PALMETTO FOR 2 MONTHS. AN IMPROVEMENT IN SYMPTOM SCORE OF 50% OR GREATER AFTER TREATMENT WITH SAW PALMETTO FOR 2, 4, AND 6 MONTHS WAS NOTED IN 21% (10 OF 48), 30% (14 OF 47), AND 46%
(21 OF 46) OF PATIENTS, RESPECTIVELY. THERE WAS NO SIGNIFICANT CHANGE IN PEAK URINARY FLOW RATE, POSTVOID RESIDUAL URINE VOLUME, OR DETRUSOR PRESSURE AT PEAK FLOW AMONG PATIENTS COMPLETING THE STUDY. NO SIGNIFICANT CHANGE IN MEAN SERUM PSA
LEVEL WAS NOTED. |